Glenmark Pharmaceuticals USA to launch potassium phosphates injection USP
Elmwood Park, March 16
Glenmark Pharmaceuticals Inc USA has announced the upcoming launch of 'Potassium Phosphates Injection USP', 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials.
According to a statement released by the pharmaceutical company, "Glenmark's Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi [NDA 212832].
The release also stated that Glenmark will begin distribution in March 2026.
According to the sales data from IQVIA, the Potassium Phosphates Injection market in the US recorded annual sales of about $50.7 million for the 12-month period ending January 2026.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We look forward to growing our portfolio of products within the institutional channel with the upcoming launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials. We continue to strengthen our commitment to bring quality and affordable alternatives to market for patients in need with each injectable launch."
— ANI
Reader Comments
As someone in the healthcare sector, I appreciate the detailed breakdown. A $50+ million market is significant. Launching in 2026 gives them time to ensure quality. Hope this success translates to more affordable medicines back home too.
The technical specs are impressive, but I always wonder if the focus on foreign markets means less R&D for diseases prevalent in India. Still, it's a business and they're doing well. More power to them!
Working in a US hospital pharmacy, having more generic alternatives like this from reliable companies is crucial for managing costs. Glenmark has a good reputation. Looking forward to seeing it on our formulary.
This is how you build brand India globally - through quality and science. Not just IT, but our pharmaceutical sector is a true world leader. Jai Hind!
While the launch is positive, I hope Glenmark ensures the supply chain for this injection is robust. Sometimes these niche hospital products face shortages. Planning for 2026 is a good sign though.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.